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Abstract 
Machine learning (ML), deep learning (DL), 
and artificial intelligence (AI) are of increasing 
importance in biomedicine. The goal of this work is to 
show progress in ML in digital health, to exemplify 
future needs and trends, and to identify any essential 
prerequisites of AI and ML for precision health. 
High-throughput technologies are delivering 
growing volumes of biomedical data, such as large-
scale genome-wide sequencing assays, libraries of 
medical images, or drug perturbation screens of 
healthy, developing, and diseased tissue. Multi-omics 
data in biomedicine is deep and complex, offering an 
opportunity for data-driven insights and automated 
disease classification. Learning from these data will 
open our understanding and definition of healthy 
baselines and disease signatures. State-of-the-art 
applications of deep neural networks include digital 
image recognition, single cell clustering, and virtual 
drug screens, demonstrating breadths and power of 
ML in biomedicine. 
Significantly, AI and systems biology have 
embraced big data challenges and may enable novel 
biotechnology-derived therapies to facilitate the 
implementation of precision medicine approaches. 
Introduction 
In the past decade, advances in genetic 
disease and precision oncology have resulted in an 
increased demand for predictive assays that enable 
the selection and stratification of patients for 
treatment (1). The enormous divergence of signaling 
and transcriptional networks mediating the cross talk 
between healthy, diseased, stromal and immune cells 
complicates the development of functionally relevant 
biomarkers based on a single gene or protein. 
Unexpectedly, the conclusion of the human 
genome did not translate into a burst of new drugs. 
The pharmaceutical industry rather announced a 
declining output in terms of the number of new drugs 
approved despite increasing commercial efforts of 
drug research and development (2, 3). In contrast, 
machine learning (ML) as well as network and 
systems biology are innovating with impactful 
discoveries and are now starting to be seamlessly 
integrated into the biomedical discovery pipeline (4). 
A major ambition of medical artificial 
intelligence (AI) lies in translating patient data to 
successful therapies. Machine learning models face 
particular challenges in biomedicine such as the size 
of the library to train the model, data input 
conversion problems, transfer, overfitting, ignorance 
of confounders, and many more (5-7). They may 
require new infrastructures, while making possibly 
just recently established workflows obsolete. On the 
other hand, deep neural network (DNN) approaches 
may offer distinct benefits. Such opportunities for 
deep learning (DL) in biomedicine include scalability, 
handling of extreme data heterogeneity, as well as 
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the ability to transfer learning (8), or if wanted even 
the possibility not to depend on data supervision at 
all (9). 
The goal of this work is to show progress in 
ML in digital health and exemplify needs, trends, and 
requirements for AI and ML for precision medicine. 
Digital image recognition, single cell analysis, and 
virtual screens demonstrate breadths and power of 
ML in biomedicine. 
Enabling synergies between artificial 
intelligence and digital pathology 
Advances in pattern recognition and image 
processing have enabled synergies between AI 
technology and modern pathology (10, 11). In 
particular, DL architectures such as deep 
convolutional neural networks have achieved 
unprecedented performance in image classification 
and gaming tasks (12-15). The expression “digital 
pathology” was coined when referring to advanced 
slide-scanning techniques in combination with AI-
based approaches for the detection, segmentation, 
scoring, and diagnosis of digitized whole-slide images 
(16). 
In pathology, quantifying and standardizing 
clinical outcome remains a challenge. Accurate 
grading, staging, classifying, and quantifying response 
to treatment by computer-assisted technologies are 
important recent initiatives (17, 18). Neural network 
algorithms perform well in a setting where either 
large amounts of input data or high quality training 
sets are provided. Using a digital archive of more than 
100,000 clinical images of skin disease such 
prerequisites were fulfilled and a deep convolutional 
neural network was successfully trained to classify 
skin lesions comparable with current quality 
standards in pathology (19). Given such an intuitive 
image-based analysis, a mechanistic understanding of 
the convoluted layers is not necessary and the 
approach could be transferred to patient-based 
mobile phone platforms to enhance early detection 
and cancer prevention (20-22). In the future, specific 
DNN modules will replace selected steps of the 
traditional pathology workflow. By looking at 
different computational image-recognition tasks, 
already today, particularly strong performance of DL 
is already observed in segmentation tasks nuclei, 
epithelia or tubules, immune infiltration by 
lymphocyte classification, cell cycle characterization 
and mitosis quantification, and grading of tumors. 
Over time, the transition toward the digital pathology 
lab will lead to more accurate drug response 
prediction and prognosis of this underlying disease 
(23). 
Digital healthcare and clinical health 
records 
ML can learn from almost any data type, 
even unstructured medical text, such as patient 
records, medical notes, prescriptions, audio interview 
transcripts, or pathology and radiology reports. 
Future day-to-day applications will embrace ML 
methods to organize a growing volume of scientific 
literature, facilitating access and extraction of 
meaningful knowledge content from it (24). In the 
clinic, ML can harness the potential of electronic 
health records to accurately predict medical events 
(25). By implementing a ranking function in the 
content network, one can overcome heterogeneity of 
clinical or healthcare provider-specific electronic 
health records, inherent to the current medical 
practice around the world (26). 
Multi-omics integration 
A defined goal of precision medicine is to 
predict the best treatment strategy for the patient. 
Drug responses in combination with genomic, 
epigenomic, transcriptomic, proteomic, metabolomic 
profiling data provide accurate network prediction to 
the perturbation. Using multi-omics data, including 
somatic copy number alterations, somatic exome 
mutations, methylomes, and transcriptomes of 1000 
cell lines, ML can be utilized in a modeling exercise to 
predict genomic features for process and drug 
response prediction (27). Top-performing methods 
exploit ML, integrate multiple profiling data sets, and 
enhance scoring by regression models to predict drug 
sensitivities (28-30). Given convolution and non-
linear relationship between transcriptomic, 
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epigenomic, and metabolic functions, future ML 
applications can be challenged to resolve intricate 
multi-omics patterns (31). Precision oncology has 
been showcased by implementing patient-derived 
cancer cell lines (32). Such bench-to-bedside models 
can provide real-time drug response predictions and 
often create of massive knowledge banks accessible 
to ML workup. In future, the ability to screen patient-
derived avatars will inform about resistance 
mechanisms and facilitate evidence-based medicine, 
even of complex traits (33). 
Machine detection of resistance signatures 
Somatic alterations in cancer frequently 
escape the recognition by the endogenous immune 
system, creating resistance (34). Even though 
excellent efficacy and some complete remissions 
have been seen in a limited number of melanoma 
patients, some of whom may be regarded as cured of 
cancer, many malignancies show resistance or lack of 
response of long duration with these agents. 
Predicting tumor responses to immune checkpoint 
blockade remains a major challenge and an active 
field of research fueled by systems biology and AI 
approaches (18). 
Deciphering epigenomic networks 
Epigenomics of oncogenic networks has an 
ability to accurately predict regulome function, 
epigenomic-transcriptomic cooperation, and disease 
progression (35). Then again, epigenetic 
modifications on chromatin, DNA, and RNA are 
complex and often context-specific, making their 
mechanistic understanding challenging. Elastic net is 
a shrinkage method hybrid of ridge and lasso 
regularization (preventing over-fitting) able to handle 
ultra-high dimensional regression and suitable for 
epigenomic data (36). Using such methods, metabolic 
and epigenomic data have been used to establish 
biomarkers and to predict clocks in aging (37, 38). 
Enhanced by ML methods, epigenetic marks including 
promoter methylation are utilized as a continuous 
readout of transcriptional accessibility and molecular 
processes that guide development, tissue 
maintenance, disease states, and eventually aging. 
Given progress in multiplex barcoding, new data 
challenges in the field of epigenomics are quickly at 
hand. Frontiers include processing and machine 
integration of sequencing and chromatin accessibility 
information derived from the transcriptome and 
epigenome of the same cell (39). 
Visualizing and exploring cellular 
heterogeneity at single cell resolution 
In single cell biology, ML and DL are 
frequently utilized to investigate the diversity and 
complexity of cell populations. In cancer, single cell 
methods provide a view of heterogeneity that 
recognizes the impact of diverse cell states and types 
surrounding the tumor microenvironment. Further, 
cancer is a dynamic and highly heterogeneous disease 
composed of a mix of clones characterized by distinct 
genotypes pushing bulk sequencing methods to their 
limits. Profiling of copy numbers, transcripts, or 
chromatin accessibility together with cluster analysis 
can uncover differences, even in seemingly 
homogenous tissues and resolve subclonal 
complexity. Dimensionality reduction and clustering 
are typical ML techniques employed to visualize 
single cell transcriptomics (scRNA-Seq) data. In 
particular, the clustering algorithm Louvain 
community detection is robust for high-dimensional 
data like scRNA-Seq matrices. The human cell atlas 
(40), whose primary goal is to establish, discover, and 
catalogue different cell populations ab initio, creates 
unsupervised maps, serving as a resource for 
subsequent disease-directed studies. In addition, it is 
possible to predict cycle, disease progression, and 
perturbation responses using deep network 
approaches (41-45). 
Spatial transcriptomics (spRNA-Seq) 
combines the benefits of traditional histopathology 
with single cell gene expression profiling. The ability 
to connect the spatial organization of molecules in 
cells and tissues with their gene expression state 
enables mapping of specific disease pathology (46, 
47). ML has the ability to decode molecular 
proximities from sequencing information and 
construct images of gene transcripts at sub-cellular 
resolution (48). 
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Artificial intelligence in chemical 
informatics and drug discovery 
Chemical informatics has an ability to predict 
novel drug targets, quantify ADME and toxicology, 
match drugs with targets and biological activities, 
model physicochemical properties, accelerate data 
mining, predict biological targets for compounds on a 
large scale, design new chemicals and syntheses (49), 
and analyze large virtual chemical spaces (50). Such a 
new paradigm enables medicinal chemists to process 
billions of molecules in virtual screens (51, 52). By 
tightly integrating database knowledge, AI, and lab 
automation it is possible to accelerate the drug 
discovery pipeline and select structures that can be 
prepared on automated systems and made available 
for biological testing, allowing for timely hypothesis 
testing and validation. 
Computational analyses of drug-
perturbation assays have the ability to predict the 
activities of the compounds on seemingly unrelated 
biological processes (53). ML can provide insight into 
drug mechanism, create correlative bridges between 
disjoint nodes, establish biomarkers, repurpose 
existing drugs, optimize drug candidates, design 
clinical trials, and even recruit for clinical trials. 
Image-based drug fingerprints were demonstrated to 
enable biological activity prediction for drug 
discovery, even when a chemical library in 
combination with high-content image screening was 
repurposed. Potential applications of predictions 
delivered by implemented computational models 
were far beyond the intended target of the original 
compound screen (54). 
Conclusion 
Biomedical science of genomic signatures, 
image processing, and drug discovery rapidly adopted 
big data opportunities and new learning-based 
technologies. From traditional approaches relying on 
leads from nature to brute-force screening using 
robotics, following the introduction of several other 
disruptive technologies, artificial intelligence is yet 
another pivotal moment toward a rationalized, data 
driven process in healthcare and pharmaceutical 
industry. Machine intelligence and deep networks are 
changing our approach to medical bioinformatics at 
an unprecedented speed. As a result, the decision-
making processes in precision medicine will shift from 
an algorithm-centric to a data-centric insight. 
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